Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NQO1 | P15559 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27996814 | 0.94 | CYP3A4 (0.53) | LTA4HCA12CA1CA2CA7 | |
| SCHEMBL98351 | 0.91 | LTA4H (0.57) | LTA4HCA12CA1CA2CA7 | |
| 1,4-Dipropoxybenzene SCHEMBL122039 | 0.87 | LTA4H (0.67) | LTA4HCA12CA1CA2CA7 | |
| SCHEMBL1119457 | 0.86 | NR5A1 (0.62) | LTA4HLMNAMAPTNPC1RAB9A | |
| SCHEMBL13808346 | 0.85 | LTA4H (0.64) | LTA4HCA12CA1CA2CA7 | |
| SCHEMBL3092648 | 0.85 | NR5A1 (0.66) | LTA4HLMNAMAPTNPC1RAB9A | |
| SCHEMBL10878033 | 0.85 | NR5A1 (0.66) | LTA4HLMNAMAPTNPC1RAB9A | |
| SCHEMBL1119584 | 0.85 | NR5A1 (0.66) | LTA4HLMNAMAPTNPC1RAB9A | |
| SCHEMBL2094301 | 0.85 | NR5A1 (0.66) | LTA4HLMNAMAPTNPC1RAB9A | |
| SCHEMBL2093730 | 0.85 | NR5A1 (0.66) | LTA4HLMNAMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2544535-B1 | PHENOXY THIOPHENE SULFONAMIDES AND THEIR USE AS INHIBITORS OF GLUCURONIDASE | NORTH CAROLINA CENTRAL UNIV (US) | 2017-04-19 | — | — | EP | claimed |
| US-9617239-B2 | Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2017-04-11 | — | — | US | claimed |
| WO-2006103119-A2 | TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-10-05 | — | — | WO | claimed |
| US-6768024-B1 | CONTROLLING OBESITY, SEXUAL DYSFUNCTION OR INFLAMMATION | LION BIOSCIENCE AG (DE) | 2004-07-27 | — | — | US | claimed |
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| US-4591376-A | PLANT GROWTH REGULATORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-05-27 | — | — | US | claimed |
| EP-0126234-A2 | 1,2,3-Thiadiazol-3-in-5-ylidene ureas, their preparation and compositions as plant-growth regulators and defoliants | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-11-28 | — | — | EP | claimed |
| US-3966711-A | 4-Alkyl-1,4-diaza-5-oxo-cycloheptanes and their 1-oxyls | CIBA-GEIGY CORPORATION (US) | 1976-06-29 | — | — | US | claimed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-9631048-B2 | Sulfonium compounds, their preparation and use | BASF SE (DE) | 2017-04-25 | — | — | US | disclosed |
| EP-1389216-B1 | AVERMECTINS SUBSTITUTED IN THE 4\"-POSITION HAVING PESTICIDAL PROPERTIES | MERIAL INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20160039795-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-11 | — | — | US | disclosed |
| EP-0015639-A2 | Enantiomers of triazole compounds, a process for preparing them, their use as plant fungicides and growth regulating agents and compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-09-17 | — | — | EP | disclosed |
| US-4015007-A | Heterocyclic spiro compounds | CIBA-GEIGY CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-3971757-A | STABILIZERS FOR POLYMERS | CIBA-GEIGY CORPORATION (US) | 1976-07-27 | — | — | US | disclosed |
| US-3966711-A | 4-Alkyl-1,4-diaza-5-oxo-cycloheptanes and their 1-oxyls | CIBA-GEIGY CORPORATION (US) | 1976-06-29 | — | — | US | disclosed |
| US-3954729-A | FROM A SECONDARY AMINE, CARBONYL SULFIDE, AND AN ALKYL HALIDE | IHARA CHEMICAL INDUSTRY CO., LTD. (JA) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039795-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | LTA4H 2295/4885CA12 4018/4885CA1 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.